News Reader.info

ABSTRACT Statin therapy response is highly variable. Variants of lipid metabolism genes and statin pharmacokinetic modulators could play a role, however, the impact of most of these variants

remains unconfirmed. A prospective and multicenter study included 252 patients was carried out in order to assess, according to achievement of LDL-C or non-HDL-C therapeutic targets and

quantitative changes in lipid profiles, the impact of _CETP, ABCA1, CYP2D6_, and _CYP2C9_ gene candidate variants on the simvastatin, atorvastatin, and rosuvastatin response. Patients

carrier _ABCA1_ rs2230806 and _CYP2D6*3_ variants are less likely to achieve therapeutic lipid targets (_p_ = 0.020, OR = 0.59 [0.37, 0.93]; _p_ = 0.040, OR = 0.23 [0.05, 0.93],

respectively). Among CETP variants, rs708272 was linked to a 10.56% smaller reduction in LDL-C with rosuvastatin (95% CI = [1.27, 19.86] %; _p_ = 0.028). In contrast, carriers of rs5882 had

a 13.33% greater reduction in LDL-C (95% CI = [25.38, 1.28]; _p_ = 0.032). If these findings are confirmed, ABCA1, CYP2D6, and CETP genotyping could be used to help predict which statin and

dosage is appropriate in order to improve personalized medicine. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 6 print issues and online access $259.00 per year only $43.17 per issue Learn more Buy this article *

Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn

about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS LIPID LOWERING EFFECTS OF THE CETP INHIBITOR OBICETRAPIB IN COMBINATION

WITH HIGH-INTENSITY STATINS: A RANDOMIZED PHASE 2 TRIAL Article 11 August 2022 DUTCH PHARMACOGENETICS WORKING GROUP (DPWG) GUIDELINE FOR THE GENE-DRUG INTERACTION BETWEEN _SLCO1B1_ AND

STATINS AND _CYP2C9_ AND SULFONYLUREAS Article 15 December 2024 ENDOTHELIAL CELL-RELATED GENETIC VARIANTS IDENTIFY LDL CHOLESTEROL-SENSITIVE INDIVIDUALS WHO DERIVE GREATER BENEFIT FROM

AGGRESSIVE LIPID LOWERING Article 26 February 2025 REFERENCES * Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density

lipoprotein colesterol reduction: The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5:257–64.

Article  CAS  PubMed  Google Scholar  * Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004;47:73–104. Article  CAS  PubMed  Google Scholar  *

Verschuren JJW, Trompet S, Wessels JAM, Guchelaar HJ, de Maat MP, Simoons ML, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?

Eur Heart J. 2012;33:165–75. Article  PubMed  CAS  Google Scholar  * Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-genome and candidate gene analysis

for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2:173–81. Article  CAS  PubMed  Google Scholar  * Vrablík M, Hubáček JA, Dlouhá D,

Lánská V, Rynekrová J, Zlatohlávek L, et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res. 2012;61:609–17. Article  PubMed  Google Scholar  *

Munshi A. Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke. Hum Genet. 2012;131:1775–81. Article  CAS  PubMed  Google Scholar  *

Deepak Voora, Svati HS, Reed CR, Zhai J, Crosslin DR, Messer C, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ

Cardiovasc Genet. 2008;1:100–6. Article  CAS  Google Scholar  * Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and

cholesterol reduction. JAMA. 2004;291:2821–7. Article  CAS  PubMed  Google Scholar  * Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Common genetic variation in

the ABCB1 gene is associated with the cholesterol-owering effect of simvastatin in males. Pharmacogenomics. 2009;10:1743–51. Article  CAS  PubMed  Google Scholar  * Martin NG, Li KW, Murray

H, Putt W, Packard CJ, Humphries SE. The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol. 2012;73:303–6. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL

cholesterol response to statins. Nat Commun. 2014;5:5068. Article  CAS  PubMed  Google Scholar  * Ruiz-Iruela C, Padró-Miquel A, Pintó-Sala X, Baena-Díez N, Caixàs-Pedragós A, Güell-Miró R,

et al. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment. PLoS ONE. 2018;13:e0205430. Article  PubMed  PubMed Central  CAS  Google Scholar  * Feng Q, Wei-Qi

W, Chung C, Levinson R, Bastarache L, Joshua C, et al. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J. 2017;17:204–8. Article

  CAS  PubMed  Google Scholar  * Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with

lipoprotein levels and cardiovascular risk. JAMA. 2017;318:947–56. Article  CAS  PubMed  PubMed Central  Google Scholar  * Li YY, Zhang H, Qin XY, Lu XZ, Yang B, Chen ML. ATP-binding

cassette transporter A1 R219K polymorphism and coronary artery disease in Chinese population: a meta-analysis of 5,388 participants. Mol Biol Rep. 2012;39:11031–9. Article  CAS  PubMed 

Google Scholar  * Tall AR. Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk. J Clin Lipidol. 2010;4:389–93. Article  PubMed  PubMed Central 

Google Scholar  * Rocha KC, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol. 2018;14:613–24. Article

  CAS  PubMed  Google Scholar  * Kashani Farid MA, Azizi F, Hedayati M, Daneshpour MS, Shamshiri AR, Siassi F. Association between CETP Taq1B and LIPC −514 C/T polymor- phisms with the serum

lipid levels in a group of Tehran’s population: a cross sectional study. Lipids Health Dis. 2010;9:96. Article  PubMed  PubMed Central  CAS  Google Scholar  * De Haan W, van der Hoogt CC,

Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis.

2008;197:57–63. Article  PubMed  CAS  Google Scholar  * Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, et al. CETP genotype predicts increased mortality in

statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792–9. Article  CAS  PubMed  Google Scholar  * Carlquist JF, Muhlestein

JB, Horne BD, Hart NI, Bair TL, Molhuizen H, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant

coronary artery disease. Am Heart J. 2003;146:1007–14. Article  CAS  PubMed  Google Scholar  * Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of

CETP in lipid levels and disease. J Lipid Res. 2003;44:1080–93. Article  CAS  PubMed  Google Scholar  * Anagnostopoulou K, Kolovou G, Kostakou P, Mihas C, Mikhailidis D, Cokkinos DV.

Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother. 2007;8:2459–63. Article  CAS  PubMed 

Google Scholar  * Ma XY, Liu JP, Song ZY. Associations of the ATP-binding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: a meta-analysis.

Atherosclerosis. 2011;215:428–34. Article  CAS  PubMed  Google Scholar  * Lu Z, Luo Z, Jia A, Yu L, Muhammad I, Zeng W, et al. Associations of the ABCA1 gene polymorphisms with plasma lipid

levels: a meta-analysis. Medicine. 2018;97:e13521. Article  CAS  PubMed  PubMed Central  Google Scholar  * Ghaznavi H, Aali E, Soltanpour MS. Association study of the atp-binding cassette

transporter A1 (ABCA1) Rs2230806 genetic variation with lipid profile and coronary artery disease risk in an Iranian population. Open Access Maced J Med Sci. 2018;6:274–9. Article  PubMed 

PubMed Central  Google Scholar  * Rejeb J, Omezzine A, Rebhi L, Boumaiza I, Kchock K, Belkahla R, et al. Associations between common polymorphisms of adenosine triphosphate-binding cassette

transporter A1 and coronary artery disease in a Tunisian population. Arch Cardiovasc Dis. 2010;103:530–7. Article  PubMed  Google Scholar  * Li J, Wang LF, Li ZQ, Pan W. Effect of R219K

polymorphism of the ABCA1 gene on the lipidlowering effect of pravastatin in Chinese patients with coronary heart disease. Clin Exp Pharm Physiol. 2009;36:567–70. Article  CAS  Google

Scholar  * Akao H, Polisecki E, Schaefer EJ, Trompet S, Robertson M, Ford I, et al. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.

Atherosclerosis. 2014;235:176–81. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kitzmiller JP, Luzum JA, Dauki A, Krauss RM, Medina MW. Candidate-gene study of functional

polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci. 2017;10:172–7. Article  CAS  PubMed  Google Scholar  * Kitzmiller JP, Mikulik EB,

Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics Personalized Med. 2016;9:97–106. Article  CAS  Google

Scholar  * Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet.

2008;47:463–74. Article  CAS  PubMed  Google Scholar  * Buzková H, Pechandová K, Danzig V, Vareka T, Perlik F, Zak A, et al. Lipid-lowering effect of fluvastatin in relation to cytochrome

P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit. 2012;18:CR512–17. Article  PubMed  PubMed Central  Google Scholar  * Fujino H, Saito T, Tsunenari Y,

Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004;34:961–71. Article  CAS  PubMed  Google Scholar  * Zuccaro P,

Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to

simvastatin and fluvastatin. Pharm Res. 2007;55:310–7. Article  CAS  Google Scholar  * Geisel J, Kivistö KT, Griese EU, Eichelbaum M. The efficacy of simvastatin is not influenced by CYP2D6

polymorphism. Clin Pharm Ther. 2002;72:595–6. Google Scholar  * Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Position paper. Statin intolerance-an attempt at a

unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1–23. Article  CAS  PubMed  PubMed Central  Google Scholar  * Ramsey LB, Johnson SG, Caudle

KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol

Ther. 2014;96:423–8. Article  CAS  Google Scholar  * ACC/AHA Release Updated Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD Risk. Am Fam Phys. 2014;90:260–5. * Third Report

of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report.

Circulation. 2002;106:3143–421. Article  Google Scholar  * Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without

use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. Article  CAS  PubMed  Google Scholar  * A global reference for human genetic variation. The 1000 Genomes Project

Consortium. Nature. 2015;526:68–74. Article  CAS  Google Scholar  * Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a toolset for whole-genome association

and population-based linkage analysis. Am J Hum Genet 2007;81:559–75. http://zzz.bwh.harvard.edu/plink/. Article  CAS  PubMed  PubMed Central  Google Scholar  * Crews KR, Gaedigk A,

Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharm Ther. 2014;95:376–82.

Article  CAS  Google Scholar  * Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study

populations. PLoS ONE. 2010;5:e9763. Article  PubMed  PubMed Central  CAS  Google Scholar  * Phillips MC. Is ABCA1 a lipid transfer protein? J Lipid Res. 2018;59:749–63. Article  CAS  PubMed

  PubMed Central  Google Scholar  * Liu Y, Tang C. Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta. 2011;1821:522–9. Article  PubMed  PubMed Central  CAS  Google

Scholar  * Zhao GJ, Yin K, Fu YC, Tang CK. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med. 2012;18:149–58. Article 

PubMed Central  CAS  Google Scholar  * Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durrwell A, Bucklar-Suchankova G, et al. Statin-induced decrease in ATP-binding cassette transporter A1

expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther. 2015;29:7–14. Article  CAS  PubMed  Google Scholar  * Gaedigk A,

Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, PharmVar Steering Committee. The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome

P450 (CYP) allele nomenclature database. Clin Pharm Ther 2018;103:399–401. Article  CAS  Google Scholar  * Li J, Wang X, Zhang Z, Zou J, Chen Y, Wang X, et al. Statin therapy correlated

CYP2D6 gene polymorphism and hiperlipidemia. Curr Med Res Opin. 2014;30:223–8. Article  PubMed  CAS  Google Scholar  * Dagostino C, Allegri M, Napolioni V, Bignami E, Mutti A, van Schaik

RHN. CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. Pharmgenomics

Pers Med. 2018;11:179–91. CAS  PubMed  PubMed Central  Google Scholar  * Cronin-Fenton DP, Lash TL. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer

outcomes. Expert Rev Clin Pharmacol 2011;4:363–77. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nieto-Ramirez I, Chegwin-Angarita C, Atehortúa L, Sepúlveda L. Statins: chemistry,

analytical techniques, biosynthesis and pharmacokinetics. Vitae. 2013;20:49–63. CAS  Google Scholar  * Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al.

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–88. Article  CAS  PubMed  Google Scholar  *

Leusink M, Onland-Moret NC, de Bakker PI, de Boer A, Maitland-van der Zee AH. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17:163–80. Article  CAS

  PubMed  Google Scholar  * Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to

CETP mass and high-density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000;20:507–15. Article  CAS  PubMed  Google Scholar 

Download references ACKNOWLEDGEMENTS We thank Arnald Alonso-Pastor, Emili Corbella-Inglés, Ferran Trias-Vilagut, Marta Fanlo- Maresma, Hannia Elena Lafuente-González, Xavier Jusmet, and

Enric Juncadella-García who provided insight and expertize that greatly assisted the research. We also would like to thank to Mollet Hospital (FSM, Mollet del Vallès, Spain) for their

unstiting support in this project. The present work was performed as part of the Biochemistry, Molecular Biology and Biomedicine doctoral program of Cristina Ruiz-Iruela at Universitat

Autònoma de Barcelona (Barcelona, Spain). FUNDINGS This research was supported by Fundació Parc Taulí Institut Universitari UAB (Parc Taulí recerca scholarship 2012, CSPT/CIR/2012) and

Fundación José Luis Castaño (FENIN scholarship 2014, JLC/FENIN/2014) from the Spanish Society of Laboratory Medicine (SEQC). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Clinical

Laboratory, IDIBELL-Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain Cristina Ruiz-Iruela, Beatriz Candás-Estébanez, Pedro Alía-Ramos & Ariadna

Padró-Miquel * phD student at Universitat Autònoma de Barcelona, Barcelona, Spain Cristina Ruiz-Iruela * Cardiovascular Unit, IDIBELL-Hospital Universitari de Bellvitge, L’Hospitalet de

Llobregat, Barcelona, Spain Xavier Pintó-Sala * Genetics Laboratory UDIAT-CD, Corporació Sanitària Parc Tauli, Sabadell, Barcelona, Spain Neus Baena-Díez * Endocrinology Department,

Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain Assumpta Caixàs-Pedragós * Hospitalet Clinical Laboratory, Centre Atenció Primària Just Oliveras, L’Hospitalet de Llobregat,

Barcelona, Spain Roser Güell-Miró & Rosa Navarro-Badal * Clinical Laboratory, Hospital Universitario Miguel Servet, Zaragoza, Spain Pilar Calmarza & Jose Luis Puzo-Foncilla Authors *

Cristina Ruiz-Iruela View author publications You can also search for this author inPubMed Google Scholar * Beatriz Candás-Estébanez View author publications You can also search for this

author inPubMed Google Scholar * Xavier Pintó-Sala View author publications You can also search for this author inPubMed Google Scholar * Neus Baena-Díez View author publications You can

also search for this author inPubMed Google Scholar * Assumpta Caixàs-Pedragós View author publications You can also search for this author inPubMed Google Scholar * Roser Güell-Miró View

author publications You can also search for this author inPubMed Google Scholar * Rosa Navarro-Badal View author publications You can also search for this author inPubMed Google Scholar *

Pilar Calmarza View author publications You can also search for this author inPubMed Google Scholar * Jose Luis Puzo-Foncilla View author publications You can also search for this author

inPubMed Google Scholar * Pedro Alía-Ramos View author publications You can also search for this author inPubMed Google Scholar * Ariadna Padró-Miquel View author publications You can also

search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Cristina Ruiz-Iruela. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no

conflict of interest. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

SUPPLEMENTARY INFORMATION GENOTYPE DISTRIBUTION AND LINKAGE DISEQUILIBRIUM STUDY RESULTS RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Ruiz-Iruela, C.,

Candás-Estébanez, B., Pintó-Sala, X. _et al._ Genetic contribution to lipid target achievement with statin therapy: a prospective study. _Pharmacogenomics J_ 20, 494–504 (2020).

https://doi.org/10.1038/s41397-019-0136-7 Download citation * Received: 11 August 2019 * Revised: 21 November 2019 * Accepted: 26 November 2019 * Published: 06 December 2019 * Issue Date:

June 2020 * DOI: https://doi.org/10.1038/s41397-019-0136-7 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative